MSI2 and breast cancer: For example, LINC00942 promotes chemoresistance in gastric cancer (GC) by suppressing MSI2 degradation to enhance c-Myc stability [21], lnc-SEMA3B-AS1 inhibits breast cancer (BC) progression by targeting miR-3940/KLLN axis [22], and VCAN-AS1 competitively binds with eIF4A3 to reduce TP53 expression and contributes to the progression of GC [23].